Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal [PDF]
EBioMedicine, 2016 Persistence of latently infected cells in presence of Anti-Retroviral Therapy presents the main obstacle to HIV-1 eradication. Much effort is thus placed on identification of compounds capable of HIV-1 latency reversal in order to render infected cells ...
Mateusz Stoszko +10 more
doaj +4 more sources
Leveraging Novel Integrated Single-Cell Analyses to Define HIV-1 Latency Reversal [PDF]
Viruses, 2021 While suppressive antiretroviral therapy can effectively limit HIV-1 replication and evolution, it leaves behind a residual pool of integrated viral genomes that persist in a state of reversible nonproductive infection, referred to as the HIV-1 reservoir.
Suhui Zhao, Athe Tsibris
doaj +2 more sources
Bioactive Compounds from Euphorbia usambarica Pax. with HIV-1 Latency Reversal Activity [PDF]
Pharmaceuticals, 2021 Euphorbia usambarica is a traditional medicine used for gynecologic, endocrine, and urogenital illnesses in East Africa; however, its constituents and bioactivities have not been investigated.
Yu-Chi Tsai +9 more
doaj +2 more sources
Natural killer cells induce HIV-1 latency reversal after treatment with pan-caspase inhibitors [PDF]
Frontiers in Immunology, 2022 The establishment of a latency reservoir is the major obstacle for a cure of HIV-1. The shock-and-kill strategy aims to reactivate HIV-1 replication in HIV -1 latently infected cells, exposing the HIV-1-infected cells to cytotoxic lymphocytes.
Joana Furtado Milão +7 more
doaj +2 more sources
Schlafen 12 restricts HIV-1 latency reversal by a codon-usage dependent post-transcriptional block in CD4+ T cells [PDF]
Communications Biology, 2023 Latency is a major barrier towards virus elimination in HIV-1-infected individuals. Yet, the mechanisms that contribute to the maintenance of HIV-1 latency are incompletely understood.
Mie Kobayashi-Ishihara +22 more
doaj +2 more sources
HIV-1 latency reversal agent boosting is not limited by opioid use [PDF]
JCI InsightOpioid use may affect the HIV-1 reservoir and its reversal from latency. We studied 47 virally suppressed people with HIV (PWH) and observed that lower concentration of HIV-1 latency reversal agents (LRAs), used with small molecules that did not reverse ...
Tyler Lilie +11 more
doaj +2 more sources
The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate. [PDF]
PLoS ONE, 2019 Antiretroviral therapy (ART) suppresses HIV replication, but does not cure the infection because replication-competent virus persists within latently infected CD4+ T cells throughout years of therapy. These reservoirs contain integrated HIV-1 genomes and
Michael Bobardt +7 more
doaj +2 more sources
Release of P-TEFb from the Super Elongation Complex promotes HIV-1 latency reversal. [PDF]
PLoS PathogensThe persistence of HIV-1 in long-lived latent reservoirs during suppressive antiretroviral therapy (ART) remains one of the principal barriers to a functional cure. Blocks to transcriptional elongation play a central role in maintaining the latent state,
William J Cisneros +11 more
doaj +2 more sources
Emerging Microbes and InfectionsTo date, an affordable, effective treatment for an HIV-1 cure remains only a concept with most “latency reversal” agents (LRAs) lacking specificity for the latent HIV-1 reservoir and failing in early clinical trials.
Minh Ha Ngo +25 more
doaj +3 more sources
Breaking into HIV-1’s Epigenetic Vault: Cure Strategies to Eliminate the Viral Reservoir [PDF]
VirusesHuman immunodeficiency virus type 1 (HIV-1) is a retrovirus that integrates into the host cell’s DNA as a provirus. Transcription from the provirus is regulated in large part by cellular proteins and epigenetic factors.
Joanna E. Jones +3 more
doaj +2 more sources